-+ 0.00%
-+ 0.00%
-+ 0.00%

Laekna expects H1 net loss no more than RMB 5 million

PUBT·08/17/2026 00:01:40
Listen to the news
Laekna expects H1 net loss no more than RMB 5 million
  • Laekna guided for RMB 145 million to RMB 155 million revenue for the six months ended June 30, 2026, versus nil a year earlier.
  • Net loss forecast at no more than RMB 5 million, versus about RMB 130 million previously, implying a 96% year-on-year reduction.
  • Improved outlook tied to revenue recognized from exclusive license deals covering LAE118 with Vasque Bio, Inc. and LAE002 (afuresertib) with Qilu Pharmaceutical.
  • Interim results scheduled for publication on Aug. 25, 2026; figures based on unaudited management accounts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12285871), on August 17, 2026, and is solely responsible for the information contained therein.